The Discounted Cash Flow (DCF) valuation of JW Cayman Therapeutics Co Ltd (2126.HK) is (35.41) HKD. With the latest stock price at 5.19 HKD, the upside of JW Cayman Therapeutics Co Ltd based on DCF is -782.4%.
Based on the latest price of 5.19 HKD and our DCF valuation, JW Cayman Therapeutics Co Ltd (2126.HK) is a sell. selling 2126.HK stocks now will result in a potential gain of 782.4%.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| WACC / Discount Rate | 6.8% - 11.1% | 8.9% |
| Long-term Growth Rate | 3.0% - 5.0% | 4.0% |
| Fair Price | (95.09) - (22.29) | (35.41) |
| Upside | -1932.2% - -529.5% | -782.4% |